(MENAFN- ProactiveInvestors)
Limited () has executed the first major non-exclusive distribution agreement in the U.S. for its Travelan diarrhea treatment with Traveler’s Supply Inc.
Traveler’s Supply which specialises in domestic and international travel-related products has contracted for a minimum annual purchase volume of 50000 units.
This follows the company making its initial U.S. sales in April 2015 to the country’s largest travel medicine chain with over 240 clinics providing travel medicine services.
’s Travelan is marketed as a dietary supplement in the U.S. allowing it to be sold in pharmacies drug stores and general stores.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.